GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay $2.2 billion to 10 plaintiff firms over liability cases related to its discontinued heartburn medicine ...
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...
Zantac Maker GSK Agrees To Pay $2.3 Bn In US Settlements
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
Reuters3d
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...
Los Angeles Daily News4d
GSK to settle 80,000 Zantac cases for up to $2.2 billion
GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.
Benzinga.com4d
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK will pay up to $2.2 billion to resolve 93% of U.S. Zantac cases. GSK expects to recognize a £1.8 billion ($2.3 billion) charge in Q3 2024 related to these settlements. These cases account for ...
CNN3d
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...